


FY 2026 President's Budget Summary

The FY 2026 Budget provides \$6.8 billion for FDA, an overall decrease of -\$271.0 million (-3.9 percent) compared to the FY 2025 Enacted level. This includes \$3.2 billion in discretionary budget authority, a decrease of -\$408.8 million (-11.4 percent), and \$3.6 billion in user fees, an increase of +\$137.3 million (+4.0 percent). FDA's budget request reflects the Agency's support of the Make America Healthy Again (MAHA) agenda in key areas of importance for human and animal health.

Make America Healthy Again

FDA's FY 2026 Budget includes \$234.6 million to support targeted MAHA activities to address the nation's chronic disease epidemic, restore trust in our food system, and strengthen America's nutritional and food safety. The net increase to the Human Foods Program is +\$65.5 million. This investment will ensure the safety of the U.S. food supply, invest in nutrition, prevent food safety failures, prevent infant formula contamination and shortages, and restore laboratory operations to conduct gold standard science. FDA requires funding to protect the nation's food supply by removing unsafe additives used in foods, help schools transition to healthier foods to ensure children are served wholesome food, and strengthen the food safety system to protect American consumers from preventable harm.



Continuity of User Fee Funding for Medical Devices

The Budget includes a total increase of \$118.2 million to ensure that the Devices Program can continue collecting and spending user fee funding needed to review new medical devices. User fees help FDA ensure predictable timelines for product review and sustain staffing levels necessary to review products expeditiously. Within this enhancement, \$5.4 million is provided to advance MAHA initiatives as they pertain to improving health outcomes, supporting innovation,

and reducing the burden of chronic diseases. This program will also advance MAHA initiatives related to improving health outcomes, supporting innovation, and reducing the burden of chronic diseases.

Promoting Efficiency through Consolidation of Core Functions

In alignment with the Administration's focus on promoting government efficiency, FDA has begun and will continue to consolidate work to core functions and mission-critical activities. The Budget request includes a total reduction of -\$169.4 million to support executive orders directing U.S. government-wide contract and spending efficiency initiatives. It also includes a decrease of -1,940 FTEs and -\$456.6 million in budget authority to support the reduction of federal bureaucracy initiative. FDA is streamlining functions and fostering innovation in workflow management to enable the Agency to shift towards a more efficient operating model. FDA will restore public trust through radical transparency, effectiveness, and judicious financial management.

Infrastructure: Facilities, Investments, and Rent

The FY 2026 Budget includes a total budget authority decrease of -\$87.1 million below the FY 2025 Enacted level. FDA continues to assess its infrastructure requirements to ensure alignment to the Administration's goals. FDA will continue operating, maintaining, and securing its headquarters, the White Oak campus. The Agency will continue maintenance of its buildings and infrastructure. In accordance with the reduction in GSA rent funding, the Agency will reduce its physical footprint across the country. FDA will continue to assess its infrastructure requirements to ensure alignment to the Administration's goals.

21st Century Cures Act

The Budget provides no additional funding (-\$50.0 million) due to the end of the authorized funding from the 21st Century Cures Act, as of FY 2026.

User Fees

User fees are critical to enabling FDA to fulfill its mission of protecting public health. The Agency uses user fees to strengthen its efficiency and increase the speed at which products are available to the public. The FY 2026 Budget includes a total of \$3.6 billion in user fees.